RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Members will acquire treatment until disorder progression or the members are unable to tolerate the study drugs.For all flow cytometry experiments, ten,000 cells per replicate ended up analyzed, and three replicates fo